Table 1.
Clinical information for 51 patients used in this study and 68 patients in the validation cohort.
| Cohort | Training cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
| Full | Short survivors | Long survivors | Full | Short survivors | Long survivors | |
| Total samples | 51 | 14 | 13 | 68 | 16 | 11 |
| T stage | ||||||
| 1 | 3 | 0 | 2 | 0 | 0 | 0 |
| 2 | 12 | 3 | 4 | 4 | 0 | 3 |
| 3 | 31 | 10 | 5 | 60 | 14 | 7 |
| 4 | 5 | 1 | 2 | 1 | 0 | 0 |
| TX | 0 | 0 | 0 | 3 | 2 | 1 |
| N stage | ||||||
| N0 | 14 | 3 | 5 | 19 | 5 | 6 |
| N1 | 37 | 11 | 8 | 46 | 9 | 4 |
| NX | 0 | 0 | 0 | 3 | 2 | 1 |
| M stage | ||||||
| M0 | 48 | 13 | 13 | 2 | 0 | 0 |
| M1 | 1 | 0 | 0 | 3 | 2 | 0 |
| MX | 2 | 1 | 0 | 63 | 14 | 11 |
| Median overall survival days (Standard error) | 572 (109.7) | 216 (24.0) | 1544 (230.2) | 413.5 (45.2) | 211.5 (23.6) | 1054 (87.9) |
| Median age (Standard error) | 66 (1.6) | 71 (2.3) | 64 (3.9) | 68 (1.3) | 70.5 (2.9) | 64 (2.6) |
| Diabetes status | ||||||
| Yes | 22 | 4 | 7 | 0 | 0 | 0 |
| No | 29 | 10 | 6 | 0 | 0 | 0 |
| N/A | 0 | 0 | 0 | 68 | 16 | 11 |
| Sex | ||||||
| Male | 32 | 9 | 8 | 33 | 7 | 5 |
| Female | 19 | 5 | 5 | 35 | 9 | 6 |
| Race | ||||||
| Caucasian | 44 | 10 | 12 | 0 | 0 | 0 |
| African‐American | 6 | 3 | 1 | 0 | 0 | 0 |
| N/A | 1 | 1 | 0 | 68 | 16 | 11 |